Researcher tending seedlings in a laboratory environment. PHOTO: FREEPIK
Bindwell is testing a simple idea: use AI to design smarter, more targeted pesticides built for today’s farming challenges.
Updated
November 14, 2025 10:48 PM
Researcher tending seedlings in a laboratory environment. PHOTO: FREEPIK
Bindwell, a San Francisco–based ag-tech startup using AI to design new pesticide molecules, has raised US$6 million in seed funding, co-led by General Catalyst and A Capital, with participation from SV Angel and Y Combinator founder Paul Graham. The round will help the company expand its lab in San Carlos, hire more technical talent and advance its first pesticide candidates toward validation.
Even as pesticide use has doubled over the last 30 years, farmers still lose up to 40% of global crops to pests and disease. The core issue is resistance: pests are adapting faster than the industry can update its tools. As a result, farmers often rely on larger amounts of the same outdated chemicals, even as they deliver diminishing returns.
Meanwhile, innovation in the agrochemical sector has slowed, leaving the industry struggling to keep up with rapidly evolving pests. This is the gap Bindwell is targeting. Instead of updating old chemicals, the company uses AI to find completely new compounds designed for today’s pests and farming conditions.
This vision is made even more striking by the people leading it. Bindwell was founded by 18-year-old Tyler Rose and 19-year-old Navvye Anand, who met at the Wolfram Summer Research Program in 2023. Both had deep ties to agriculture — Rose in China and Anand in India — witnessing up close how pest outbreaks and chemical dependence burdened farmers.
Filling the gap in today’s pesticide pipeline, Bindwell created an AI system that can design and evaluate new molecules long before they hit the lab. It starts with Foldwell, the company’s protein-structure model, which helps map the shapes of pest proteins so scientists know where a molecule should bind. Then comes PLAPT, which can scan through every known synthesized compound in just a few hours to see which ones might actually work. For biopesticides, they use APPT, a model tuned to spot protein-to-protein interactions and shown to outperform existing tools on industry benchmarks.
Bindwell isn’t selling AI tools. Instead, the company develops the molecules itself and licenses them to major agrochemical players. Owning the full discovery process lets the team bake in safety, selectivity and environmental considerations from day one. It also allows Bindwell to plug directly into the pipelines that produce commercial pesticides — just with a fundamentally different engine powering the science.
At present, the team is now testing its first AI-generated candidates in its San Carlos lab and is in early talks with established pesticide manufacturers about potential licensing deals. For Rose and Anand, the long-term vision is simple: create pest control that works without repeating the mistakes of the last half-century. As they put it, the goal is not to escalate chemical use but to design molecules that are more precise, less harmful and resilient against resistance from the start.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
November 5, 2025 3:47 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.